| pubmed-article:11165318 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11165318 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:11165318 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:11165318 | lifeskim:mentions | umls-concept:C0079427 | lld:lifeskim |
| pubmed-article:11165318 | lifeskim:mentions | umls-concept:C0449721 | lld:lifeskim |
| pubmed-article:11165318 | lifeskim:mentions | umls-concept:C0032214 | lld:lifeskim |
| pubmed-article:11165318 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11165318 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11165318 | pubmed:abstractText | Although loss of heterozygosity (LOH) on the short arm of chromosome 8 has been frequently observed in human prostate cancer, the relationship between LOH and clinical background is poorly understood. Fluorescence in situ hybridization (FISH) was employed to evaluate the chromosomal deletion on 8p in 42 prostate cancers using a centromeric probe for chromosome 8, in combination with 4 cosmid probes spanning 8p12 to 8p22. Deletions for at least one locus on the 8p were observed in 29 (69.0%) tumors. The most frequently deleted regions were 8p22 (54.8%) and 8p21.3 (52.4%), in almost the same frequency. The second most frequently deleted region was 8p21.1-p21.2 (38.1%). Deletions of 8p22 and 8p21.3 significantly correlated with tumor grade (P=0.0034, Fisher's exact probability test). A significantly higher frequency of the deletion on 8p21.1-p21.2 was observed in advanced prostate cancer (beyond capsular penetration or positive nodal metastases) than in localized prostate cancer (P=0.0033). In particular, deletion of 8p21.1-p21.2 was more frequently observed in the cases with lymph node metastases than without them (P=0.0029). No clinicopathological parameters had significant relation to deletions on 8p12. These results suggest that deletions on 8p22-p21.3 play an important role in tumor differentiation, while an 8p21.1-p21.2 deletion plays a role in the progression of prostate cancer. | lld:pubmed |
| pubmed-article:11165318 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11165318 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11165318 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11165318 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11165318 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:11165318 | pubmed:issn | 0165-4608 | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:ObiSS | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:TakahashiMM | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:MatsuyamaHH | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:NaitoKK | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:YoshihiraAA | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:KishiFF | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:KinjoMM | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:TsukamotoMM | lld:pubmed |
| pubmed-article:11165318 | pubmed:author | pubmed-author:SagiyamaKK | lld:pubmed |
| pubmed-article:11165318 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11165318 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11165318 | pubmed:volume | 124 | lld:pubmed |
| pubmed-article:11165318 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11165318 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11165318 | pubmed:pagination | 20-6 | lld:pubmed |
| pubmed-article:11165318 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:meshHeading | pubmed-meshheading:11165318... | lld:pubmed |
| pubmed-article:11165318 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11165318 | pubmed:articleTitle | Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. | lld:pubmed |
| pubmed-article:11165318 | pubmed:affiliation | Department of Urology, Yamaguchi University School of Medicine, 1-1 Minami-Kogushi, Ube, Japan. | lld:pubmed |
| pubmed-article:11165318 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11165318 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11165318 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11165318 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11165318 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11165318 | lld:pubmed |
